IKBKG (nuclear factor-κB essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function - 15/08/11
, Erwin W. Gelfand, MD a, ⁎
Abstract |
Background |
Patients with hypomorphic nuclear factor-κB essential modulator (NEMO) mutations have extensive phenotypic variability that can include atypical infectious susceptibility.
Objective |
This study may provide important insight into immunologic mechanisms of host defense.
Methods |
Immunologic evaluation, including studies of Toll-like receptor (TLR) function, was performed in a 6-month-old boy with normal ectodermal development who was diagnosed with Pneumocystis pneumonia and cytomegalovirus sepsis.
Results |
Genomic and cDNA sequencing demonstrated a novel NEMO missense mutation, 337G->A, predicted to cause a D113N (aspartic acid to asparagine) substitution in the first coiled-coil region of the NEMO protein. Quantitative serum immunoglobulins, lymphocyte subset numbers, and mitogen-induced lymphocyte proliferation were essentially normal. The PBMC responses to TLR ligands were also surprisingly normal, whereas natural killer cell cytolytic activity, T-cell proliferative responses to specific antigens, and T-cell receptor–induced NF-κB activation were diminished.
Conclusion |
Unlike the unique NEMO mutation described here, the most commonly reported mutations are clustered at the 3′ end in the tenth exon, which encodes a zinc finger domain. Because specific hypomorphic variants of NEMO are associated with distinctive phenotypes, this particular NEMO mutation highlights a dispensability of the region including amino acid 113 for TLR signaling and ectodysplasin A receptor function. This region is required for certain immunoreceptor functions as demonstrated by his susceptibility to infections as well as natural killer cell and T-cell defects.
Le texte complet de cet article est disponible en PDF.Key words : NEMO, Toll-like receptors
Abbreviations used : IκB, IKK, NEMO, NF-κB, NK, TCR, TLR
Plan
| Supported in part by grants from the US Immunodeficiency Network and Philadelphia Department of Health (J.S.O.), and by the Jeffrey Model Diagnostic Center at the Children’s Hospital of Philadelphia. |
|
| Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest. |
Vol 121 - N° 4
P. 976-982 - avril 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
